Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen discontinues development of CETP inhibitor

Amgen Inc. (NASDAQ:AMGN) discontinued internal development of cholesteryl ester transfer protein (CETP)

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE